Neurocrine Biosciences presented real-world data showing how classic congenital adrenal hyperplasia (CAH) affects patients differently across life stages, from childhood growth monitoring to adult health complexities. The study used decades of medical records to map patient journeys, highlighting ongoing treatment demands and impacts on daily life, education, and work. These insights aim to help healthcare providers anticipate changing patient needs and improve support and care coordination. The findings were shared at the Endocrine Nurses Society Annual Symposium 2026 and underscore the importance of tailored, lifelong management strategies for CAH.
Neurocrine Biosciences (NBIX) shares are trading at USD 137.09 on Pluang as of Oct 16, 2026 19:12 WIB, showing a modest 0.10% increase in the past day. The stock has a market cap of $13.92 billion and a 52-week trading range between $123.10 and $185.50. Pluang investors currently hold the stock for an average of 24 days, with all recent orders being buys, reflecting steady interest in the health sector company.
